Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures

MHRA advises monitoring of serum phosphate levels in patients treated with multiple high-doses, or those on long-term treatment, and in those with pre-existing risk factors for hypophosphataemia; and re-evaluating treatment in patients with persistent hypophosphataemia.

Source:

Medicines and Healthcare products Regulatory Agency